Hanqing Dong
A5084792895- Protein Degradation and Inhibitors
- Advanced Breast Cancer Therapies
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Prostate Cancer Treatment and Research
- Chromatin Remodeling and Cancer
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
Arvinas (United States)
2016-2024
Abstract Purpose: Estrogen receptor (ER) alpha signaling is a known driver of ER-positive (ER+)/human epidermal growth factor 2 negative (HER2−) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become central strategy in the treatment ER+ advanced However, suboptimal ER inhibition and resistance resulting from ESR1 mutation dictates that new therapies are needed. Experimental Design: A medicinal chemistry campaign identified...
381 Background: The Androgen Receptor (AR) remains the principal driver of castration-resistant prostate cancer during transition from a localized to metastatic disease. Most patients initially respond inhibitors AR pathway, but response is often short-lived. majority progressing on enzalutamide or abiraterone exhibit genetic alterations in locus, either form amplifications point mutations gene. Given these mechanisms resistance, our goal eliminate protein using PROteolysis TArgeting Chimera...
267 Background: The transition from localized prostate cancer to metastatic disease often involves modulation of the Androgen Receptor (AR). During progression, patients progressing on enzalutamide or abiraterone therapy exhibit amplified AR, increased intra-tumoral androgen production AR mutations leading promiscuity other ligands. Therefore, is still principal driver disease. Methods: A novel approach block signaling specifically target for degradation. To this end, we have developed...
<div>AbstractPurpose:<p>Estrogen receptor (ER) alpha signaling is a known driver of ER-positive (ER<sup>+</sup>)/human epidermal growth factor 2 negative (HER2<sup>−</sup>) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become central strategy in the treatment ER<sup>+</sup> advanced However, suboptimal ER inhibition and resistance resulting from <i>ESR1</i> mutation...
<p>Supplementary Tables S1-S4 and Figures S1-S16</p>
<p>Extended Methods</p>
<div>AbstractPurpose:<p>Estrogen receptor (ER) alpha signaling is a known driver of ER-positive (ER<sup>+</sup>)/human epidermal growth factor 2 negative (HER2<sup>−</sup>) breast cancer. Combining endocrine therapy (ET) such as fulvestrant with CDK4/6, mTOR, or PI3K inhibitors has become central strategy in the treatment ER<sup>+</sup> advanced However, suboptimal ER inhibition and resistance resulting from <i>ESR1</i> mutation...
<p>Extended Methods</p>
<p>Supplementary Tables S1-S4 and Figures S1-S16</p>